Phuturdex › Diseases › Central nervous system disease
Drugs in development · updated 30 October 2026
Central nervous system disease: drugs in development
As of 30 October 2026 there are 31 active clinical trials (recruiting or ongoing, phases I–III) on 38 drugs for central nervous system disease. 20 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ambroxol Hydrochloride | III | 1 | NCT05778617 |
| Ecopipam | III | 1 | NCT06021522 |
| ECUR-506 | III | 1 | NCT06255782 |
| ML-007C-MA | II | 3 | NCT07459647 |
| 4D-310 | I–II | 2 | NCT05629559 |
| ACI-24.060 | I–II | 1 | NCT05462106 |
| ALN-6457 | I–II | 1 | NCT07832370 |
| BIA 28-6156 | II | 1 | NCT05819359 |
| CTH120 | II | 1 | NCT07654114 |
| FBX-101 | I–II | 1 | NCT05739643 |
| GSK4527226 | II | 1 | NCT07105709 |
| Neflamapimod | II | 1 | NCT07033481 |
| SilevertinibBDTX-1535 | II | 1 | NCT07326566 |
| VIM0423 | II | 1 | NCT07804615 |
| ATI-105 | I | 1 | NCT07869654 |
| G207 | I | 1 | NCT03911388 |
| LY3954068 | I | 1 | NCT06297590 |
| NG004 | I | 1 | NCT06817577 |
| NIO752 | I | 1 | NCT05469360 |
| ZR001 | I | 1 | NCT07718659 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | III | 2 | NCT05508789 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| TenecteplaseTnkase®, Metalyse® | II–III | 1 | NCT05105633 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| AbemaciclibLY2835219, Verzenio® | I–II | 1 | NCT05386108 |
| Bevacizumabavastin, MVASI | I–II | 1 | NCT07681297 |
| CapecitabineXeloda, Capectitabine Tablets | I–II | 1 | NCT07681297 |
| ElacestrantOrserdu® | I–II | 1 | NCT05386108 |
| EthambutolMyambutol® | II | 1 | NCT05383742 |
| IsoniazidNydrazid®, Rimifon® | II | 1 | NCT05383742 |
| LinezolidLinezolid In Sodium Chloride 0.9% In Plastic Container®, Zyvox® | II | 1 | NCT05383742 |
| Pyrazinamide | II | 1 | NCT05383742 |
| RifampicinRifampin, RIFADIN | II | 1 | NCT05383742 |
| TemozolomideTemodal, Temodar | II | 1 | NCT07326566 |
Sorted by most advanced phase and number of active trials. Showing 15 of 18 drugs.
All 38 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Brain Neoplasms 190 drugs
- Alzheimer's disease 157 drugs
- Ischemic stroke 94 drugs
- Parkinson's disease 104 drugs
- Amyotrophic lateral sclerosis 79 drugs
- Stroke 70 drugs
- Glioma 184 drugs
- Cognitive dysfunction 94 drugs
- Glioblastoma 245 drugs
- Epilepsy 44 drugs
- Dementia 54 drugs
- Migraine 28 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Nutritional and metabolic diseases 5 drugs
- Neurologic Manifestations 15 drugs
- Brain Diseases 23 drugs
- Neurobehavioral manifestation 8 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002493 “Central Nervous System Diseases”.